US price pressure threatens Switzerland’s pharmaceutical pipeline, industry warns

Switzerland’s pharmaceutical model is facing a pressure test with consequences far beyond the pharmacy counter. René Buholzer, CEO of Interpharma, warns that US pricing policy is making Swiss prices strategically dangerous for companies developing and launching new medicines.

The conflict is stark. Switzerland wants affordable treatment and tighter control of health costs. Pharmaceutical companies, facing a global development bill that has soared to $2.23 billion per new drug, argue that a low Swiss price can reverberate through the world’s largest medicine market.

Buholzer says the country’s framework conditions are deteriorating quickly enough to threaten both innovation and economic strength. A recent analysis cited by Interpharma projects that Switzerland’s pharmaceutical industry could be smaller in 2040 than it is today if conditions do not improve.

That warning lands in a country where pharmaceuticals are a major economic force and a significant source of tax revenue. The industry now wants the federal “Life Sciences Location” working group to confront an uncomfortable trade-off: driving prices down may offer short-term relief for insurers and households, while weakening the sector could erode investment, medicine availability and public revenues over time.

The debate is no longer theoretical. Switzerland is being forced to decide how much it is willing to pay to remain a preferred location for pharmaceutical research and access.

One-third of medicines approved by Swissmedic are no longer being submitted for reimbursement by health insurers. That figure, cited by Buholzer, captures the widening gap between regulatory approval and practical access.

A medicine can clear Switzerland’s safety and efficacy requirements yet still fail to reach the reimbursement process that determines whether patients can routinely obtain it through the health system. For patients, the result can be delayed access or fewer therapeutic options. For companies, it signals that Switzerland’s relatively small market may not justify the commercial and administrative risks of entry.

Buholzer describes the trend as long-term, but says it has worsened dramatically. He points to years of policy at the Federal Office of Public Health that prioritised cost reduction over security of supply. The new US approach, he argues, is accelerating that movement by turning Swiss prices into a global reference point.

The tension is particularly sharp in Switzerland’s decentralised healthcare landscape, where federal regulation, insurers, cantons and patients all bear different parts of the cost. Cutting prices may appear decisive on paper. However, if companies respond by withholding submissions, the savings can come with a less visible cost: medicines that are approved in principle but absent from ordinary Swiss coverage.

That access gap is now becoming a central test of health policy.

A Swiss price can now echo across the Atlantic. Buholzer says the United States has introduced an international reference-pricing system that examines a basket of countries including Switzerland. That turns Swiss pricing decisions into potential benchmarks for American negotiations and calculations.

The mathematics creates a powerful asymmetry. Switzerland is a small market; the United States is enormous. If a company accepts a lower net price in Switzerland, it risks seeing that figure used to push down revenues across a far larger market. Buholzer’s blunt assessment is that “a low price in tiny Switzerland would massively reduce revenues in the enormous US market.”

This changes the industry’s response to Swiss discounts. Politicians have considered allowing discounts through a revision of health-insurance regulations, but Interpharma argues that the traditional tool no longer works if the United States demands the net price—the amount left after discounts.

In that scenario, a confidential or negotiated reduction in Switzerland may still affect international pricing calculations. Companies could therefore decide that the safest option is to forgo the Swiss market altogether, particularly for new products with uncertain demand.

The result would be a policy paradox: a mechanism designed to lower costs could discourage launches, narrow choice and weaken Switzerland’s leverage as a life-sciences hub.

Developing a new medicine now costs an average of $2.23 billion—and that bill has risen 65% in a decade. The figure covers the journey from discovery to launch for the world’s 20 largest biopharmaceutical companies, according to a related Swissinfo analysis.

That surge intensifies the commercial calculation facing drugmakers. Research is expensive, failure is common and the global revenue window is limited. Every launch market matters, but not every market carries the same weight. Switzerland offers scientific credibility and a strong life-sciences ecosystem; its population, however, is small compared with the United States.

For Swiss policymakers, the challenge is to preserve affordability without making the country commercially unattractive. Industry representatives are not simply demanding a blank cheque. Buholzer says higher prices may be necessary to safeguard supply under changed global conditions, but he also says Interpharma is open to alternative financing arrangements.

Possible approaches include a dedicated fund, savings generated from off-patent medicines, or shifting how costs are distributed among the federal government, cantons, insurers and patients. Each option carries political risks. A fund could protect access but require new public spending; savings elsewhere could create winners and losers; shifting costs could intensify pressure on premiums.

The numbers leave Switzerland with little room for delay. As development costs soar, pricing policy increasingly determines where innovation appears—and where it does not.

Switzerland must now choose whether its cheapest price is also its most expensive mistake. The immediate dispute centres on medicine prices, but the stakes reach into research, supply security, tax receipts and the country’s international standing.

Interpharma’s warning is deliberately stark: without better framework conditions, the pharmaceutical industry will shrink, and Switzerland’s tax revenues will decline. That is an industry claim, not an independent government forecast, but it points to a broader policy dilemma. The country cannot assess drug pricing only through the premium on an insurance bill; it must also measure the cost of delayed launches, reduced investment and weaker resilience.

Meanwhile, households are already sensitive to health-insurance premiums. Any solution that raises headline prices risks public backlash, particularly if it appears to reward companies without demanding savings elsewhere. That is why Buholzer says the industry is open to a fund, off-patent savings or a different distribution of costs.

The federal working group on the “Life Sciences Location” now faces a narrow window to reconcile those competing pressures. Switzerland needs medicines that patients can access, prices that the health system can sustain and conditions that keep research and production anchored domestically.

The next decision will define more than a reimbursement rule. It will help determine whether Switzerland remains a pharmaceutical leader—or becomes a market companies increasingly choose to bypass.